242
Participants
Start Date
December 31, 2015
Primary Completion Date
March 31, 2020
Study Completion Date
May 31, 2021
IMP321 (eftilagimod alpha)
In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
Placebo
In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
Paclitaxel
Paclitaxel will be given in both treatment arms (classified as Non IMP)
Szent Margit Kórház Onkológiai Osztály, Budapest
MH Egészségügyi Központ Onkológiai Osztály, Budapest
VU University Medical Center, Amsterdam
Cliniques universitaires Saint-Luc - Institut Roi Albert II - Cancérologie et Hématologie Oncologie clinique, Brussels
AZ Sint-Maarten, Duffel
GZA Ziekenhuizen campus Sint-Augustinus Oncologische Research, Wilrijk
Universitair Ziekenhuis Antwerpen Breast and Gynecological Oncology Unit, Edegem
UZ Leuven, campus Gasthuisberg Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven
Erasmus MC, Rotterdam
Clinique Sainte-Elisabeth, Namur
Zuyderland MC, Geleen
MUMC Medical Oncology department, Maastricht
AZ Sint-Jan Burgge-Oostende, Bruges
AZ Nikolass, Sint-Niklaas
UMCG Medisch Centrum Groningen, Groningen
Institut Claudius Regaud - IUC Toulouse - Oncopôle, Toulouse
Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez
KEM- Brustzentrum der Kliniken Essen-Mitte, Essen
Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus Centrum für Hämatologie und Onkologie, Frankfurt
NCT - Nationales Centrum für Tumorerkrankungen, Heidelberg
UFKT - Universitäts-Frauenklinik Tübingen, Tübingen
UFU - Universitätsfrauenklinik Ulm, Ulm
Institut Curie / Centre René Huguenin, Saint-Cloud
HMC Antoniushove, Leidschendam
VieCuri Medisch Centrum, Venlo
Kierownik Oddziału Onkologii i Radioterapii Szpital Morski im. PCK w Gdyni, Gdynia
St James' Institute of Oncology, Leeds
The Christie NHS Foundation Trust The Christie Clinic - Medical Oncology, Manchester
Nottingham University Hospitals NHS Trust, Nottingham
Immutep S.A.S.
INDUSTRY